Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Phase 2 Study to Evaluate OBI-833/OBI-821 Maintenance Therapy in Patients With Globo H-Positive Advanced Biliary Tract Cancer Not Progresseding Under First-Line Gemcitabine and Cisplatin

NCT06490198 is registered in ClinicalTrials.gov with Chang Gung Memorial Hospital as lead sponsor.

NCT NCT06490198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06490198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Phase 2 Study to Evaluate OBI-833/OBI-821 Maintenance Therapy in Patients With Globo H-Positive Advanced Biliary Tract Cancer Not Progresseding Under First-Line Gemcitabine and Cisplatin
Lead sponsor
Chang Gung Memorial Hospital
Phase
Phase 1
Overall status
Not yet recruiting
Start date
July 31, 2024
Completion date
July 31, 2027
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy effect, cholangiocarcinoma, immunotherapy